7723f502_s___Medical_Oncologists___ESMO__Topic
[Date] 14 Apr 2014 [Title] A Subset of Breast Cancer Patients Most Likely to Benefit From Neoadjuvant Regimen With Pan-HER Inhibitor Neratinib [Topic] 
Breast cancer - Anticancer agents & Biologic therapy
Oncology News | Medical Oncologists | ESMO